Article Text

Download PDFPDF
Mpox vaccination in a patient on anti-IL-23 therapy was well tolerated and led to seroconversion
  1. Harm-Henning Lindhof
  1. Department of Dermatology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany
  1. Correspondence to Dr Harm-Henning Lindhof, Department of Dermatology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany; Harm-Henning.Lindhof{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To address the raise in Mpox cases, in July 2022, Germany started a pre-exposure or postexposure vaccination programme with the modified vaccinia Ankara virus vaccine (Imvanex/Jynneos).1 As this is a live vaccine, there are constrains for certain patient groups. Current indications for interleukin (IL) 23 antibodies advise against the simultaneous use of live vaccines and recommend a 21-week washout after antibody therapy.2

We report on a 38-year-old HIV-negative man who was receiving treatment with the anti-IL-23 antibody risankizumab (150 mg every 3 months) for psoriasis vulgaris when he was assessed to be at high risk for Mpox. He had not previously received …

View Full Text


  • Handling editor Anna Maria Geretti

  • Contributors H-HL planned, conducted and reported the work described in the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.